Acute pancreatitis approach

Acute pancreatitis Microchapters
Home
American College of Gastroenterology Guidelines
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Acute Pancreatitis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic criteria
History and Symptoms
Physical Examination
Laboratory Findings
Abdominal X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Approach to Therapy
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Acute pancreatitis approach On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Acute pancreatitis approach All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Acute pancreatitis approach
CDC on Acute pancreatitis approach
Acute pancreatitis approach in the news
Blogs on Acute pancreatitis approach
Directions to Hospitals Treating Acute pancreatitis
Risk calculators and risk factors for Acute pancreatitis approach

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monish Thuvooru Muthu Kalyanaraman, M.B.B.S[2]

Approach to Therapy

This microchapter provides a framework for the overall management strategy in acute pancreatitis, including initial assessment and risk stratification, the four pillars of early management (fluid resuscitation, analgesia, nutrition, and antibiotic stewardship), and the general principles governing intervention for complications. Detailed procedural and surgical management is covered in the surgery/procedural therapy microchapter.

Initial Assessment and Risk Stratification

Acute pancreatitis is an unpredictable disease in its early course. Approximately 80% of patients have mild, self-limiting disease that resolves within a week, but 15–25% develop moderately severe or severe disease, accounting for virtually all morbidity and mortality. Because a patient with initially mild disease can rapidly progress to severe disease, close monitoring during the first 48–72 hours is essential.

At presentation, clinicians should:

• Confirm the diagnosis (revised Atlanta criteria: ≥2 of 3 — characteristic pain, lipase ≥3× ULN, confirmatory imaging).
• Assess hemodynamic status immediately and begin resuscitation as needed.
• Determine etiology (liver panel, triglycerides, calcium, focused history).
• Stratify risk using SIRS criteria and BUN — the simplest and most practical early bedside predictors of severity. The ACG 2024 guidelines emphasize that expert clinician judgment combined with SIRS assessment is as good as any complex scoring system.
• Admit patients with organ failure or SIRS to a monitored bed or ICU setting.

Risk factors for severe disease (ACG 2024):

• Patient characteristics: age >55, obesity (BMI >30), altered mental status, comorbidities
• ≥2 SIRS criteria at admission
• Laboratory: BUN >20 mg/dL, rising BUN, hematocrit >44%, rising hematocrit, elevated creatinine
• Imaging: pleural effusion, pulmonary infiltrates, multiple or extensive extrapancreatic collections

No scoring system reliably predicts which patients will develop severe disease — at best, approximately 50% of patients predicted to be moderately severe or severe by any system actually develop that severity. The systems are most useful for predicting mild disease (~97% accuracy), which can facilitate earlier discharge decisions.

Fluid Resuscitation

Fluid resuscitation is the cornerstone of early management. Intravascular volume depletion from third-space fluid losses contributes to organ failure and pancreatic necrosis.

Key principles (ACG 2024, AGA 2018, Gastroenterology 2024):

• Moderately aggressive fluid resuscitation is recommended (ACG 2024: conditional recommendation, low quality of evidence). The WATERFALL trial demonstrated that aggressive resuscitation (bolus 20 mL/kg followed by 3 mL/kg/h) resulted in significantly more fluid overload (20.5% vs 6.3%; adjusted RR 2.85) without improvement in the primary outcome of moderately severe or severe pancreatitis, leading to early trial termination.
• Moderate resuscitation protocol (from WATERFALL): 1.5 mL/kg/h with a 10 mL/kg bolus only if hypovolemia is present. Most patients with acute pancreatitis will benefit from approximately 3–4 L in the first 24 hours, depending on body mass.
• Lactated Ringer solution is preferred over normal saline (ACG 2024: conditional recommendation, low quality of evidence). LR is hypothesized to have anti-inflammatory properties — proposed mechanisms include calcium binding to nonesterified fatty acids and lactate-mediated reduction of pancreatic inflammation, although these mechanisms are derived primarily from preclinical studies.
• Goal-directed titration: Fluid rate should be adjusted based on clinical (heart rate <120/min, MAP 65–85 mmHg, urine output >0.5 mL/kg/h) and biochemical targets (hematocrit 35–45%, BUN trending down). Do not allow BUN or hematocrit to rise during the first 24–48 hours.
• Caution in special populations: Older adults and patients with cardiac or renal disease require careful monitoring for fluid overload, pulmonary edema, and abdominal compartment syndrome.
• Timing matters: Early hydration (first 6–12 hours) is most effective. Once severe disease is established or after 48 hours, additional hydration may be harmful.

Pain Management

Debilitating abdominal pain is the presenting symptom in the majority of patients. Current guidelines do not provide clear, consistent recommendations for analgesia in acute pancreatitis due to a remarkable paucity of level 1 evidence.

Current approach (Gastroenterology 2024, UEG/EPC 2026 guidelines):

• Multimodal analgesia is preferred, combining non-opioid and opioid agents.
• NSAIDs (e.g., diclofenac, ketorolac) are useful in mild acute pancreatitis for their anti-inflammatory and analgesic properties. Avoid in patients with acute kidney injury or active peptic ulcer disease.
• Opioids currently form the cornerstone of severe pain management (UEG/EPC 2026: GRADE-based recommendation). Current evidence does not consistently demonstrate harm from opioids in acute pancreatitis, and safety concerns should not delay their timely use. Buprenorphine demonstrated superior pain relief compared with diclofenac in a recent double-blind RCT, with comparable side-effect profiles and lower requirements for rescue analgesia.
• Step-down approach: Rather than the traditional WHO step-up ladder (designed for cancer pain), a step-down approach — starting with potent analgesia and de-escalating — may be more appropriate for the acute, self-limiting pain of acute pancreatitis.
• Epidural analgesia: Small RCTs suggest improved pancreatic perfusion and better early pain relief, but given risks of hypotension and epidural abscess, this is not routinely used.
• Patient-controlled analgesia: Requires further study; retrospective data suggest association with prolonged hospitalization and higher likelihood of discharge on opioids.

Nutrition

The traditional concept of "pancreatic rest" (NPO until pain resolution and enzyme normalization) has been definitively overturned. The pancreas is largely insensitive to meal stimulation during acute pancreatitis, and early enteral nutrition preserves gut mucosal integrity, reduces bacterial translocation, and decreases infectious complications.

Key principles (ACG 2024, AGA 2018, Gastroenterology 2024):

• Early oral feeding should be initiated as soon as tolerated — within 24 hours in mild acute pancreatitis — with a low-fat solid diet. Starting with clear liquids is not required. This approach reduces length of stay.
• Enteral over parenteral nutrition: A Cochrane meta-analysis of 8 RCTs (348 patients) demonstrated that enteral nutrition was associated with decreased mortality (RR 0.50), multiple organ failure (RR 0.55), and systemic infection (RR 0.39) compared with TPN. On subgroup analysis for severe acute pancreatitis, the mortality benefit was even more pronounced (RR 0.18), although this subgroup had limited sample size and wide confidence intervals.
• Route of enteral feeding: If oral intake is not tolerated within 72 hours, nasoenteral feeding should be initiated. Nasogastric feeding appears safe and is easier to implement than nasojejunal feeding (which requires endoscopy or interventional radiology). Either route is acceptable (ACG 2024, AGA 2018, IAP/APA 2013).
• TPN is reserved for patients who cannot tolerate enteral feeding (e.g., paralytic ileus, bowel obstruction) and should be initiated within 72 hours if enteral nutrition is not feasible.
• Nutritional screening: All patients with severe acute pancreatitis are considered at nutritional risk. Patients with mild to moderately severe acute pancreatitis should be screened using validated tools (e.g., NRS-2002).

Antibiotic Stewardship

No role for prophylactic antibiotics — this is one of the most well-established principles in acute pancreatitis management:

• Multiple double-blind, placebo-controlled RCTs and meta-analyses have consistently demonstrated that prophylactic antibiotics in severe acute pancreatitis or sterile necrosis do not reduce rates of infected necrosis, systemic complications, mortality, or need for surgical intervention (ACG 2024: conditional recommendation against, very low quality of evidence; AGA 2020; Gastroenterology 2024).
• Prophylactic antifungal therapy is also not recommended.
• Probiotic prophylaxis is not recommended. The PROPATRIA trial (2008) found significantly higher mortality in the probiotic group (16% vs 6%), although subsequent meta-analyses have not consistently replicated this mortality signal. Current guidelines advise against probiotic use in acute pancreatitis. Of note, the SCCM/ASPEN 2016 nutrition guidelines suggest considering probiotics in severe AP patients receiving early EN (low quality of evidence), representing a guideline disagreement with ACG 2024, Lancet 2020, and Gastroenterology 2024, all of which recommend against their use.

Antibiotics for suspected infected necrosis:

• Broad-spectrum IV antibiotics with good pancreatic penetration should be initiated when infected necrosis is clinically suspected (persistent fevers, rising inflammatory markers, clinical deterioration, or gas on CT). Agents include carbapenems, piperacillin-tazobactam, quinolones, metronidazole, and third-generation or higher cephalosporins.
• In clinically stable patients, antibiotics alone can serve as initial management for 2–4 weeks to allow the inflammatory reaction to organize before considering intervention. In selected cohorts, a substantial proportion of patients with infected necrosis have been successfully managed with antibiotics alone without requiring drainage or surgery, although the exact proportion varies across studies and patient populations.
• Procalcitonin may help distinguish SIRS from bacterial sepsis and guide antibiotic initiation and discontinuation. In the PROCAP trial (n=260), procalcitonin-guided care reduced antibiotic prescriptions (45% vs 63%; adjusted risk difference −15.6%; p=0.007) and total antibiotic days without increasing infection or mortality. Further multicenter validation is needed before routine adoption.

Intervention for Complications: General Principles

• Step-up approach is the standard of care for infected necrotizing pancreatitis — percutaneous or endoscopic drainage first, followed by minimally invasive necrosectomy only if clinically required. Open necrosectomy is rarely needed.
• Cholecystectomy for biliary acute pancreatitis should be performed during the index admission for mild disease (AGA 2018: moderate quality of evidence). In acute pancreatitis complicated by necrosis or fluid collections, cholecystectomy should be deferred until inflammation subsides or collections resolve/stabilize.
• ERCP is indicated urgently (within 24 hours) only for concurrent cholangitis; it is not indicated for biliary pancreatitis without cholangitis (APEC trial, Lancet 2020).
• Delay intervention when possible: Postponing necrosectomy in stable patients until ≥30 days after admission is associated with decreased mortality.

Clinically Actionable Recommendations

• Assess SIRS criteria and BUN at admission; reassess serially through the first 48–72 hours. Do not rely on complex scoring systems alone.
• Use moderately aggressive fluid resuscitation with lactated Ringer solution (approximately 1.5 mL/kg/h; bolus 10 mL/kg if hypovolemic). Do not allow BUN or hematocrit to rise. Avoid aggressive protocols (≥3 mL/kg/h) — they increase fluid overload without improving outcomes.
• Initiate early oral feeding with a low-fat solid diet as soon as tolerated. Do not wait for pain resolution or enzyme normalization.
• Do not use prophylactic antibiotics in severe acute pancreatitis or sterile necrosis (ACG 2024: conditional recommendation against, very low quality of evidence). Use therapeutic antibiotics only when infected necrosis is clinically suspected.
• For pain management, use a multimodal approach; do not withhold opioids when severe pain is present.
• Perform cholecystectomy during the index admission for mild biliary acute pancreatitis. Defer if complicated by necrosis or collections.